VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”).


Previous articleWhole-Body Effects of Psychedelics – Part 1
Next articleEntheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.